Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Eisai Subsidiary's CT Colonography System Receives Approval in Japan
August 29, 2011
- Actos Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
August 29, 2011
- Korosho to Grant Subsidies to 4 Companies to Develop, Manufacture New Flu Vaccines
August 29, 2011
- Use Medicoeconomic Evaluation in NHI Drug Pricing: Korosho Study Group
August 29, 2011
- Novartis Pharma to Ask Korosho Why It Was Not Selected for Vaccine Grant
August 29, 2011
- Korosho Orders Revision of Package Insert, “Blue Letter”for Prazaxa after 5 Deaths
August 29, 2011
- NanoCarrier Ties Up with Kyoto Univ. for Nucleic Acid Drugs
August 29, 2011
- AZ Aims to Make Nexium the No. 1 PPI in Japan
August 29, 2011
- Celsentri Approved for Naive HIV-Infected Patients: ViiV Healthcare
August 29, 2011
- AnGes MG to Jointly Develop Therapeutic HPV Vaccine with GenoLac
August 29, 2011
- RaQualia of Japan Aims to Become Global Drug Discovery Innovator
August 15, 2011
- Santen Creates Subsidiary in India
August 15, 2011
- Korosho Announces Revised Precautions for Diabetes Treatment Metgluco
August 15, 2011
- TOPICS 2 articles
August 15, 2011
- System to Ensure Early Price Settlement Necessary: Non-Partisan Council of Diet Members
August 15, 2011
- Dissolution Test Methods Annexed to ICH Q4B GLs Go into Effect
August 15, 2011
- Taisho Completes Acquisition of Malaysian Company
August 15, 2011
- EPS: Sales Up, Profits Down due to Slump of CRO Business
August 15, 2011
- JPO's WG to Resume Discussions to Revise Patent Term Extension Rule for DDS Preparations
August 15, 2011
- Asahi Kasei to Make Asahi Kasei Kuraray Medical a Wholly-owned Subsidiary
August 15, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…